{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:34:25Z","timestamp":1785551665574,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005624","name":"Hannover Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jpet.2026.104317","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:25:17Z","timestamp":1773645917000},"page":"104317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["US Food and Drug Administration black box warnings: Characteristics of drug classes and adverse effects"],"prefix":"10.1016","volume":"393","author":[{"given":"Lilly Josephine","family":"Bindel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9512-4870","authenticated-orcid":false,"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2026.104317_bib1","series-title":"Box Warning","author":"Delong","year":"2023"},{"issue":"4","key":"10.1016\/j.jpet.2026.104317_bib3","article-title":"A longitudinal analysis of black box warnings: trends and implications for drug safety","volume":"16","author":"Rajendran","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jpet.2026.104317_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.sapharm.2009.02.005","article-title":"Health care consequences of black-box warnings for antidepressants in the United States and Canada","volume":"6","author":"Nagar","year":"2010","journal-title":"Res Social Adm Pharm"},{"issue":"4","key":"10.1016\/j.jpet.2026.104317_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.12788\/acp.0084","article-title":"Black-box warnings: their consequences and how we should approach them","volume":"34","author":"Balon","year":"2022","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.jpet.2026.104317_bib6","series-title":"Global burden of preventable medication-related harm in health care: a systematic review","year":"2023"},{"issue":"3","key":"10.1016\/j.jpet.2026.104317_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archinte.166.3.338","article-title":"Adherence to black box warnings for prescription medications in outpatients","volume":"166","author":"Lasser","year":"2006","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.jpet.2026.104317_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/PTS.0000000000000101","article-title":"Prospective assessment of inpatient boxed warning prescriber adherence","volume":"13","author":"Kloet","year":"2017","journal-title":"J Patient Saf"},{"key":"10.1016\/j.jpet.2026.104317_bib9","series-title":"FDALabel","year":"2025"},{"issue":"11","key":"10.1016\/j.jpet.2026.104317_bib10","doi-asserted-by":"crossref","first-page":"8785","DOI":"10.1007\/s00210-024-03171-y","article-title":"Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022","volume":"397","author":"Bindel","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"12","key":"10.1016\/j.jpet.2026.104317_bib11","doi-asserted-by":"crossref","first-page":"18049","DOI":"10.1007\/s00210-025-04389-0","article-title":"Evidence of lithium underuse in bipolar disorder: analysis of lithium and antipsychotic consumption, prediction of future trends, regional disparities and indicators of rational and inappropriate use in Europe","volume":"398","author":"Bindel","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2026.104317_bib12","doi-asserted-by":"crossref","first-page":"10691","DOI":"10.1007\/s00210-025-03930-5","article-title":"Long-term forecasting and evaluation of medicine consumption for the ATC class H with a focus on thyroid hormones in OECD countries using ARIMA models","volume":"398","author":"Bindel","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jpet.2026.104317_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2025.107689","article-title":"Trends, prescribing patterns and projections of antiseizure drug use in Europe","volume":"218","author":"Bindel","year":"2025","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jpet.2026.104317_bib14","article-title":"Problems associated with the ATC system of drug classification","author":"Bindel","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"9","key":"10.1016\/j.jpet.2026.104317_bib15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.tips.2018.06.006","article-title":"Rethinking pharmacological nomenclature","volume":"39","author":"Seifert","year":"2018","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.jpet.2026.104317_bib16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/cpt.1554","article-title":"An analysis of follow-on development in new drug classes, January 1986-June 2018","volume":"106","author":"Lanthier","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jpet.2026.104317_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/dmd.123.001430","article-title":"Kinase inhibitors FDA approved 2018-2023: drug targets, metabolic pathways, and drug-induced toxicities","volume":"52","author":"Latham","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.jpet.2026.104317_bib18","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.3390\/ijms25105489","article-title":"Kinase inhibitors and kinase-targeted cancer therapies: recent advances and future perspectives","volume":"25","author":"Li","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2026.104317_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.107023","article-title":"IUPHAR review: recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders","volume":"199","author":"Pagare","year":"2024","journal-title":"Pharmacol Res"},{"issue":"suppl 1","key":"10.1016\/j.jpet.2026.104317_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/03007995.2024.2318058","article-title":"\u03b2-Blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications","volume":"40","author":"Taddei","year":"2024","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.jpet.2026.104317_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tips.2011.02.010","article-title":"Evolution of \u03b2-blockers: from anti-anginal drugs to ligand-directed signalling","volume":"32","author":"Baker","year":"2011","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104317_bib22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.104317_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.chembiol.2023.09.005","article-title":"Targeting RNA with synthetic oligonucleotides: clinical success invites new challenges","volume":"31","author":"Hofman","year":"2024","journal-title":"Cell Chem Biol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104317_bib24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/cpt.70048","article-title":"History and evolution of innovations in clinical pharmacology","volume":"118","author":"Lesko","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.104317_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104284","article-title":"Speed of innovation: how quickly are different therapeutic areas adopting paradigm-shifting drugs?","volume":"30","author":"Gutzeit","year":"2025","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.jpet.2026.104317_bib26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bcp.14159","article-title":"Serious adverse effects occurring after chemotherapy: a general cancer registry-based incidence survey","volume":"86","author":"Ingrand","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2026.104317_bib27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-023-00776-9","article-title":"Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship","volume":"20","author":"Lustberg","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.jpet.2026.104317_bib28","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaoncol.2019.0086","article-title":"Treatment-related complications of systemic therapy and radiotherapy","volume":"5","author":"Jairam","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jpet.2026.104317_bib29","year":"2023"},{"key":"10.1016\/j.jpet.2026.104317_bib30","series-title":"M4E(R2): the CTD \u2013 efficacy. Guidance for industry. Revision 1. U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER)","year":"2017"},{"issue":"3","key":"10.1016\/j.jpet.2026.104317_bib31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1053\/j.gastro.2007.04.075","article-title":"Crohn\u2019s disease patients\u2019 risk-benefit preferences: serious adverse event risks versus treatment efficacy","volume":"133","author":"Johnson","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jpet.2026.104317_bib32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00415-009-0084-2","article-title":"Multiple sclerosis patients\u2019 benefit-risk preferences: serious adverse event risks versus treatment efficacy","volume":"256","author":"Johnson","year":"2009","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.jpet.2026.104317_bib33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00280-023-04562-3","article-title":"Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities","volume":"92","author":"Rudd","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104317_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00002018-200730030-00005","article-title":"Drug-induced endocrine and metabolic disorders","volume":"30","author":"Ma","year":"2007","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.jpet.2026.104317_bib35","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrd3974","article-title":"Challenges and approaches for the development of safer immunomodulatory biologics","volume":"12","author":"Sathish","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpet.2026.104317_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s44337-024-00029-3","article-title":"The potential of immunomodulators in shaping the future of healthcare","volume":"1","author":"Sharma","year":"2024","journal-title":"Discov Med"},{"issue":"3","key":"10.1016\/j.jpet.2026.104317_bib37","article-title":"Toward a broader view of mechanisms of drug cardiotoxicity","volume":"2","author":"Mamoshina","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jpet.2026.104317_bib38","series-title":"Cardio-Oncology. Current Clinical Pathology","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-030-97744-3_4","article-title":"Pathophysiology of cardiac toxicity","author":"Farmakis","year":"2022"},{"issue":"2","key":"10.1016\/j.jpet.2026.104317_bib39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.therap.2023.10.008","article-title":"Drug-induced cardiac toxicity and adverse drug reactions, a narrative review","volume":"79","author":"Destere","year":"2024","journal-title":"Therapie"},{"issue":"1","key":"10.1016\/j.jpet.2026.104317_bib40","first-page":"86","article-title":"A comprehensive review on the effects of sex hormones on chemotherapy-induced cardiotoxicity: are they lucrative or unprofitable?","volume":"10","author":"Kheradkhah","year":"2024","journal-title":"Cardiooncology"},{"issue":"5","key":"10.1016\/j.jpet.2026.104317_bib41","first-page":"120","article-title":"Immunopathology and types of hypersensitivity reactions","volume":"18","author":"Renaudineau","year":"2023","journal-title":"Int J Clin Rheumatol"},{"issue":"3 Suppl","key":"10.1016\/j.jpet.2026.104317_bib42","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.jaci.2010.11.048","article-title":"Immune pathomechanism of drug hypersensitivity reactions","volume":"127","author":"Pichler","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jpet.2026.104317_bib43","series-title":"Psychotropic Drugs and Medical Conditions","first-page":"229","article-title":"The cognitive effects of psychotropic drugs","author":"Ak","year":"2017"},{"issue":"1","key":"10.1016\/j.jpet.2026.104317_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/diagnostics12010180","article-title":"The pathophysiology and the management of radiocontrast-induced nephropathy","volume":"12","author":"Cho","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jpet.2026.104317_bib45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejrad.2019.03.008","article-title":"Nephrotoxicity of iodinated contrast media: from pathophysiology to prevention strategies","volume":"116","author":"Faucon","year":"2019","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jpet.2026.104317_bib46","article-title":"Hypersensitivity reactions to iodinated contrast media: potential mechanisms and clinical management","volume":"12","author":"Zhong","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jpet.2026.104317_bib47","series-title":"FDA requests labeling changes related to safety information to clarify the benefit\/risk considerations for menopausal hormone therapies. Drug safety and availability","year":"2025"},{"key":"10.1016\/j.jpet.2026.104317_bib48","series-title":"HHS advances women\u2019s health, removes misleading FDA warnings on hormone replacement therapy","year":"2025"},{"key":"10.1016\/j.jpet.2026.104317_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13326-015-0017-1","article-title":"Exploring adverse drug events at the class level","volume":"6","author":"Winnenburg","year":"2015","journal-title":"J Biomed Semantics"},{"issue":"9","key":"10.1016\/j.jpet.2026.104317_bib50","first-page":"1031","article-title":"Drug class effects: definitions and practical applications","volume":"21","author":"Soares","year":"2002","journal-title":"Rev Port Cardiol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104317_bib51","article-title":"Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jpet.2026.104317_bib52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/CCM.0000000000004087","article-title":"Critical care management of toxicities associated with targeted agents and immunotherapies for cancer","volume":"48","author":"Gutierrez","year":"2020","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.jpet.2026.104317_bib53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit Care"},{"issue":"5","key":"10.1016\/j.jpet.2026.104317_bib54","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.4103\/jfmpc.jfmpc_1869_24","article-title":"Transformative education: enhancing pharmacovigilance awareness among healthcare professionals through sensitization initiatives","volume":"14","author":"Kumari","year":"2025","journal-title":"J Family Med Prim Care"},{"issue":"5","key":"10.1016\/j.jpet.2026.104317_bib55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7861\/clinmedicine.9-5-481","article-title":"Rational prescribing: the principles of drug selection","volume":"9","author":"Maxwell","year":"2009","journal-title":"Clin Med (Lond)"},{"issue":"17","key":"10.1016\/j.jpet.2026.104317_bib57","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1111\/bph.15916","article-title":"Perspective article: a proposal for rational drug class terminology","volume":"179","author":"Seifert","year":"2022","journal-title":"Br J Pharmacol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526005161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526005161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:13:55Z","timestamp":1777450435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526005161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0022356526005161"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104317","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"US Food and Drug Administration black box warnings: Characteristics of drug classes and adverse effects","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"104317"}}